

Literatura ACTA MEDICINAE

4/2023 Kazuistiky v onkologii, hematoonkologii a hematologii

- 2 **Dlouhodobá účinnost a bezpečnost monoterapie enzalutamidem u staršího pacienta s metastatickým kastrocně rezistentním karcinomem prostaty**
MUDr. Tomáš Pokrivčák | MUDr. Jiří Navrátil, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 2 **Úskalí volby vhodného opioidu pro onkologického pacienta – přehled**
PharmDr. Jan Šaloun, Ph.D. | PharmDr. MVDr. Vilma Vranová, Ph.D.
Ústav aplikované farmacie, Farmaceutická fakulta, Masarykova univerzita, Brno
- 2 **Záleží na etiologii hepatocelulárního karcinomu při volbě systémové terapie?**
MUDr. Marián Liberko | doc. MUDr. Renata Soumarová, Ph.D., MBA Onkologická klinika Fakultní nemocnice Královské Vinohrady a 3. LF UK, Praha, 3. LF UK, Praha
- 2 **Kam posouvá KEYTRUDA léčbu triple-negativního karcinomu prsu – reportáž**
- 3 **Neoadjuvantní léčba karcinomu prsu v roce 2023 – novinky v léčbě**
MUDr. Vlastimila Čmejlová Onkologická klinika 2. LF UK a FN v Motole, Praha
- 3 **Durvalumab v terapii bronchogenního karcinomu plic**
MUDr. Martina Gazdičková Plicní oddělení, Nemocnice AGEL Ostrava-Vítkovice, a. s.
- 3 **Časově omezená terapie kombinací venetoklaxu a obinutuzumabu v první linii léčby chronické lymfocytární leukemie**
MUDr. Dominika ěsiová | MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, Fakultní nemocnice Hradec Králové
MUDr. Petr Hoffmann, Ph.D. Radiologická klinika, Fakultní nemocnice Hradec Králové
- 4 **Léčba relabované B-akutní lymfoblastické leukemie pomocí inotuzumab ozogamicinu**
MUDr. Zdeněk Kořístek, Ph.D. Klinika hematoonkologie Fakultní nemocnice Ostrava a Lékařské fakulty Ostravské univerzity
- 4 **Léčba komplikované pravé polycytemie – od cytodeplece k ropeginterferonu**
plk. gšt. MUDr. Miloš Bohoněk, Ph.D. Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice, Praha, Fakulta biomedicínského inženýrství, České vysoké učení technické v Praze
pplk. MUDr. Dominik Kutáč, Ph.D. Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha
- 4 **Ultomiris (ravulizumab) v léčbě paroxysmální noční hemoglobinurie**
MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika FN Brno
- 4 **Přínos profylaktické aplikace koncentráту VWF/FVIII u pacienta s typem 3 von Willebrandovy choroby**
MUDr. Petr Smejkal, Ph.D. Oddělení klinické hematologie, Katedra laboratorních metod LF MU a FN Brno
- 4 **ViiV Healthcare uvádí na český trh přípravky Vocabria a Rekambys, první dlouhodobě působící injekční léčivé přípravky k léčbě HIV**
- 5 **Léčba Castlemanovy choroby: od klasické chemoterapie po biologickou léčbu**
prof. MUDr. Zdeněk Adam, CSc. | prof. MUDr. Marta Krejčí, Ph.D. | prof. MUDr. Luděk Pour, Ph.D.
Interní hematologická a onkologická klinika LF MU a FN Brno

Dlouhodobá účinnost a bezpečnost monoterapie enzalutamidem u staršího pacienta s metastatickým kastročně rezistentním karcinomem prostaty

MUDr. Tomáš Pokrivčák | MUDr. Jiří Navrátil, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Tran, C. – Ouk, S. – Clegg, N. J., et al.: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science*, 2009, 324, s. 787–790.
- 2 Scher, H. I. – Fizazi, K. – Saad, F., et al.: Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*, 2012, 367, s. 1187–1197.
- 3 Beer, T. M. – Armstrong, A. J. – Rathkopf, D. E., et al.: Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med*, 2014, 371, s. 424–433.
- 4 Shore, N. D. – Chowdhury, S. – Villers, A., et al.: Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. *Lancet Oncol*, 2016, 17, s. 153–163.
- 5 Iacovelli, R. – Ciccarese, C. – Bria, E., et al.: The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. *Clin Genitourin Cancer*, 2018, 16, s. e645–e653.
- 6 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice. *Klin Onkol*, 2014, 27, suppl. 2, s. 2519–2539.
- 7 Tagawa, S. T. – Ramaswamy, K. – Huang, A., et al.: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. *Prostate Cancer Prostatic Dis*, 2021, 24, s. 1032–1040.
- 8 Scailteux, L. M. – Campillo-Gimenez, B. – Kerbrat, S., et al.: Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014–2018 French population study (the SPEAR cohort). *Am J Epidemiol*, 2021, 190, s. 413–422.
- 9 Lee, H. Y. – Chen, H. L. – Teoh, J. Y. C., et al.: Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analysis. *Prostate Cancer Prostatic Dis*, 2021, 24, s. 244–252.
- 10 Roberto, I. – Chiara, C. – Emilio, B., et al.: The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. *Clinical Genitourinary Cancer*, 2018, 16, s. e645–e653.
- 11 Schultz, N. M. – Penson, D. F. – Wilson, S. D., et al.: Health care resource utilization and costs associated with corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. *J Manag Care Spec Pharm*, 2019, 25, s. 889–897.
- 12 Vinh-Hung, V. – Natchagande, G. – Joachim, C., et al.: Low-dose enzalutamide in late-elderly patients (≥ 75 years old) presenting with metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer*, 2020, 18, s. e660–e668.

Úskalí volby vhodného opioidu pro onkologického pacienta – přehled

PharmDr. Jan Šaloun, Ph.D. | PharmDr. MVDr. Vilma Vranová, Ph.D.

Ústav aplikované farmacie, Farmaceutická fakulta, Masarykova univerzita, Brno

- 1 Leštiňský, B. – Hakl, M.: Strategie opioidní léčby. *Neural pro praxi*, 2010, 11, s. 50–54.
- 2 Fricová, J. – Hakl, M.: Opioidy a průlomová bolest. In: Kozák, J. – Lejčko, J. – Vrba, I., et al.: *Opioidy*, Maxdorf, 2021, s. 326–335.
- 3 Juřica, J.: Duální opioidní analgezie. *Prakti lékáren*, 2022, 18, s. 48–52.
- 4 Francescangeli, J. – Karamchandani, K. – Powell, M., et al.: The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. *Int J Mol Sci*, 2019, 20, s. 2288.
- 5 Peranathan, V. – Buckley, N. A.: Opioids and antidepressants: which combinations to avoid. *Aust Prescr*, 2021, 44, s. 41–44.
- 6 Kozák, J. – Lejčko, J. – Vrba, I.: *Opioidy*. Praha, Maxdorf, 2021.
- 7 Kozáková, Š. – Goněc, R. – Rychlíčková, J., et al.: Nejčastější lékové interakce u protinádorových léčiv. *Onkologie*, 2018, 12, s. 283–286.
- 8 Seguí, H. A. – Melin, K. – Quiñones, D. S., et al.: A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. *J Transl Genet Genom*, 2020, 4, s. 263–277.
- 9 Kotlínska-Lemieszek, A. – Klepstad, P. – Haugen, D. F.: Clinically significant drug–drug interactions in involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. *Drug Des Dev Ther*, 2015, 9, s. 5255–5267.
- 10 Overholser, B. R. – Foster, D. R.: Opioid pharmacokinetic drug–drug interactions. *Am J Manag Care*, 2011, 17, s. 276–287.
- 11 Soldin, O. P. – Chung, S. H. – Mattison, D. R.: Sex differences in drug disposition. *J Biomed Biotechnol*, 2011, 2011, s. 187103.
- 12 Saiz-Rodríguez, M. – Ochoa, D. – Herrador, C., et al.: Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. *Basic Clin Pharmacol Toxicol*, 2019, 124, s. 321–329.
- 13 Fricová, J.: Bukální tablety Fentroo v léčbě průlomové bolesti u onkologických pacientů. *Acta Medicinæ*, 2021, 10, s. 52–54.
- 14 Ahn, J. S. – Lin, J. – Ogawa, S., et al.: Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. *J Pain Res*, 2017, 18, s. 1963–1972.

Záležej na etiologii hepatocelulárního karcinomu při volbě systémové terapie?

MUDr. Marián Liberko | doc. MUDr. Renata Soumarová, Ph.D., MBA Onkologická klinika Fakultní nemocnice Královské Vinohrady

a 3. LF UK, Praha, 3. LF UK, Praha

- 1 Llovet, J. M. – Castet, F. – Heikenwalder, M., et al.: Immunotherapies for hepatocellular carcinoma. *Nat Rev Clin Oncol*, 2022, 19, s. 151–172.
- 2 Reig, M. – Forner, A. – Rimola, J., et al.: BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol*, 2022, 76, s. 681–693.
- 3 Llovet, J. M. – Ricci, S. – Mazzaferro, V., et al.: SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*, 2008, 359, s. 378–390.
- 4 Cheng, A. L. – Kang, Y. K. – Chen, Z., et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*, 2009, 10, s. 25–34.
- 5 Kudo, M. – Finn, R. S. – Qin, S., et al.: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet*, 2018, 391, s. 1163–1173.
- 6 Finn, R. S. – Qin, S. – Ikeda, M., et al.: IMbrave150 Investigators: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*, 2020, 382, s. 1894–1905.
- 7 Abou-Alfa, G. K. – Chan, S. L. – Kudo, M., et al.: Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. *J Clin Oncol*, 2022, 40, s. 379.
- 8 Pfister, D. – Núñez, N. G. – Pinyol, R., et al.: NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature*, 2021, 592, s. 450–456.
- 9 Rimini, M. – Rimassa, L. – Ueshima, K., et al.: Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. *ESMO Open*, 2022, 7, s. 100591.
- 10 Casadei-Gardini, A. – Rimini, M. – Tada, T., et al.: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. *Eur J Cancer*, 2023, 180, s. 9–20.

Kam posuvá KEYTRUDA léčbu triple-negativního karcinomu prsu – reportáž

- 1 Arnedos, M., et al.: Triple-negative breast cancer: are we making headway at last? *Ther Adv Med Oncol*, 2012, 4, s. 195–210.
- 2 Bauer, K. R., et al.: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer*, 2007, 109, s. 1721–1728.
- 3 Urru, S. A. M. – Gallus, S. – Bosetti, C., et al.: Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. *BMC Cancer*, 2018, 18, s. 56.
- 4 Lin, N. U., et al.: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. *Cancer*, 2008, 113, s. 2638–2645.
- 5 Modrá kniha ČOS, březen 2022.
- 6 Cortazar, P., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- 7 Schmid, P., et al.: Pembrolizumab for early triple-negative breast cancer. *N Engl J Med*, 2020, 382, s. 810–821.
- 8 SPC KEYTRUDA, datum poslední revize textu 14. 10. 2022.
- 9 Cortes, J., et al.: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet*, 2020, 396, s. 1817–1828.
- 10 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02819518>, vyhledáno 27. 4. 2023.
- 11 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03036488>, vyhledáno 27. 4. 2023.
- 12 Schmid, P., et al.: Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*, 2022, 386, s. 556–567.
- 13 Cortes, J., et al.: Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. *N Engl J Med*, 2022, 387, s. 217–226.
- 14 Rugo, H. S., et al.: LBA16 – KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. *Ann Oncol*, 2021, 32, suppl. 5, s. S1283–S1346.

Neoadjuvantní léčba karcinomu prsu v roce 2023 – novinky v léčbě

MUDr. Vlastimila Čmejlová Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 4/2023. Dostupné z: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419>, vyhledáno 2. 5. 2023.
- 2 ESMO guidelines. Dostupné z: <https://www.esmo.org/guidelines/guidelines-by-topic/breast-cancer>, vyhledáno 2. 5. 2023.
- 3 Sparano, J. A.: TAILORx Update: 12-Year Recurrence and Survival Outcomes for Patients With Early-Stage Breast Cancer. ASCO 2022. Dostupné z: <https://ascopost.com/news/december-2022/tailorx-update-12-year-recurrence-and-survival-outcomes-for-patients-with-early-stage-breast-cancer/>, vyhledáno 2. 5. 2023.
- 4 Cardoso, F. – van't Veer, L. J. – Bogaerts, J.: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med*, 2016, 375, s. 717–729.
- 5 Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- 6 Ellis, J. M.: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. *J Clin Oncol*, 2011, 29, s. 2342–2349.
- 7 Gianni, L. – Eiermann, W. – Semiglazov, V., et al.: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet Oncol*, 2014, 15, s. 640–647.
- 8 von Minckwitz, G., et al.: Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40–GeparQuattro). *Ann Oncol*, 2014, 25, s. 81–89.
- 9 Untch, M.: Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study Groups. *J Clin Oncol*, 2011, 29, s. 3351–3357.
- 10 Jackisch, C. H.: Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. *JAMA Oncol*, 2019, 5, e190339.
- 11 Gianni, L.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. *Lancet Oncol*, 2016, 17, s. 791–800.
- 12 Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. *Eur J Cancer*, 2018, 89, s. 27–35.
- 13 Dang, Ch., et al.: BERENICE final analysis: cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer. *Cancers*, 2022, 14, s. 2596.
- 14 Tan, A. R., et al.: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. *Lancet Oncol*, 2021, 22, s. 85–97.
- 15 O'Shaughnessy, J., et al.: Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHrance5Ca): A randomised, open-label phase II study. *Eur J Cancer*, 2021, 152, s. 223–232.
- 16 von Minckwitz, G., et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- 17 Untch, M.: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 135–144.
- 18 Shepherd, J. H.: CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. *J Clin Oncol*, 2022, 40, s. 1323–1334.
- 19 Matsuda, N.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*, 2017, 376, s. 2147–2159.
- 20 Schmid, P.: Pembrolizumab for early triple-negative breast cancer. *N Engl J Med*, 2020, 382, s. 810–821.
- 21 Matsuda, N.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*, 2017, 376, s. 2147–2159.
- 22 Tutt, A.: Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med*, 2021, 384, s. 2394–2405.
- 23 Schneeweiss, A., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 24, s. 2278–2284.
- 24 Loibl, S., et al.: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. *Ann Oncol*, 2017, 28, s. 497–504.
- 25 Hurvitz, S. A., et al.: Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*, 2018, 19, s. 115–126.
- 26 Swain, S. M., et al.: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. *Ann Oncol*, 2018, 29, s. 646–653.
- 27 A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHrance5Ca). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT03674112>, vyhledáno 27. 4. 2023.
- 28 Schmid, P., et al.: Keynote-522: Phase 3 Study of Neoadjuvant Pembrolizumab + Chemotherapy, Followed by Adjuvant Pembrolizumab versus Placebo for early-stage TNBC. KN522 ESMO Virtual Plenary 2021. Dostupné z: <https://doi.org/10.1016/j.jannonc.2021.06.014>, vyhledáno 27. 4. 2023.

Durvalumab v terapii bronchogenního karcinomu plic

MUDr. Martina Gazdičková Plicní oddělení, Nemocnice AGEL Ostrava-Vítkovice, a. s.

- 1 Bilek, O.: Durvalumab in the treatment of non-small-cell lung cancer. *Klin Farmakol Farm*, 2021, 35, s. 35–39.
- 2 Lee, H. T. – Lee, J. Y. – Lim, H., et al.: Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. *Sci Rep*, 2017, 7, s. 5532.
- 3 SÚKL, <https://www.sukl.cz>.
- 4 Kiss, I., et al.: Modrá kniha ČOS ČLS JEP, 29. Aktualizace 2023. Dostupné z: <https://www.linkos.cz/files/modra-kniha/22.pdf>, s. 1–394, vyhledáno 24. 4. 2023.
- 5 Spigel, D. – Fèvre-Finn, C. – Gray, J. E., et al.: Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *J Clin Oncol*, 2022, 40, s. 1301–1311.
- 6 Paz-Ares, L. – Chen, Y. – Reinmuth, N., et al.: Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. *ESMO Open*, 2022, 7, s. 100408.

Časově omezená terapie kombinací venetoklaxu a obinutuzumabu v první linii léčby chronické lymfocytární leukemie

MUDr. Dominika Écsióvá | MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, Fakultní nemocnice Hradec Králové

MUDr. Petr Hoffmann, Ph.D. Radiologická klinika, Fakultní nemocnice Hradec Králové

- 1 Eichhorst, B., et al.: A randomized phase III study of venetoclax-based time-limited combination treatments (RVE, GVE, GIVe) vs standard chemioimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the International Intergroup GAlA (CLL13) trial. *Blood*, 2021, 138, suppl. 1, s. 71.
- 2 Seymour, J. F., et al.: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.
- 3 Smolej, L., et al.: Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie 2021. *Transfúze Hematol Dnes*, 2021, 27, s. 91–106.
- 4 Hallek, M. – Al-Sawaf, O.: Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. *Am J Hematol*, 2021, 96, s. 1679–1705.
- 5 Al-Sawaf, O., et al.: Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2020, 21, s. 1188–1200.
- 6 Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Published: 27. 11. 2017, s. 1–155. Dostupné z: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf, vyhledáno 5. 4. 2023.
- 7 Al-Sawaf, O. – Zhang, C. – Robrecht, S., et al.: Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. *Clinical Lymphoma Myeloma and Leukemia*, 2022, 22, s. S274–S275.
- 8 Seymour, J. F., et al.: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.
- 9 Fischer, K., et al.: Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med*, 2019, 380, s. 2225–2236.
- 10 Kósa, F. – Nečasová T. – Špaček, M., et al.: Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe. *Cancer Med*, 2023, 12, s. 1961–1971.
- 11 Goede, V., et al.: Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. *Haematologica*, 2014, 99, s. 1095–1100.
- 12 Linn, B. S., et al.: Cumulative illness rating scale. *J Am Geriatr Soc*, 1968, 16, s. 622–626.

Léčba relabované B-akutní lymfoblastické leukemie pomocí inotuzumab ozogamicinu

MUDr. Zdeněk Kořístek, Ph.D. Klinika hematologie Fakultní nemocnice Ostrava a Lékařské fakulty Ostravské univerzity

- 1 Gokbuget, N. – Dombret, H. – Ribera, J. M., et al.: International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. *Haematologica*, 2016, 101, s. 1524–1533.
- 2 Di Joseph, J. – Dougher, M. – Kalyandrug, L., et al.: Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. *Clin Cancer Res*, 2006, 12, s. 242–249.
- 3 Kantarjian, H. – Thomas, D. – Jorgensen, J., et al.: Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. *Lancet Oncology*, 2012, 13, s. 403–411.
- 4 Kantarjian, H. M. – DeAngelo, D. J. – Stelljes, M., et al.: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. *N Engl J Med*, 2016, 375, s. 740–753.
- 5 SPC Besponsa. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_cs.pdf, vyhledáno 24. 4. 2023.

Léčba komplikované pravé polycytemie – od cytodeplece k ropeginterferonu

plk. gšt. MUDr. Miloš Bohoněk, Ph.D. Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice, Praha, Fakulta biomedicínského inženýrství, České vysoké učení technické v Praze

plk. MUDr. Dominik Kutáč, Ph.D. Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha

- 1 Swerdlow, S. H., et al. (ed.): *WHO classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, Francie, International Agency for Research on Cancer, 2017.
- 2 Hatalova, A., et al.: Recommendations for the diagnosis and treatment of patients with polycythaemia vera. *Eur J Haematol*, 2018, doi: 10.1111/ejh.13156. Epub před tiskem. PMID: 30058088.
- 3 Doporučení České hematologické společnosti ČLS JEP: Červená kniha. Léčebné postupy v hematologii 2023, dostupné z: <https://www.hematology.cz/cervena-kniha-lecebne-postupy-v-hematologii/>, vyhledáno 21. 4. 2023.
- 4 Dulíček P.: Léčba pravé polycytemie. *Vnitř Lék*, 2018, 64, s. 955–960.
- 5 Podstavková, N., et al.: Dosavadní zkušenosti s léčbou ropeginterferonem alfa-2b u pacientů s Ph negativními myeloproliferacemi na Interní hematologické a onkologické klinice LF MU a FN Brno. *Transfuzie Hematol Dnes*, 2022, 28, s. 213–218.
- 6 Harrison, C. N., et al.: Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. *Blood*, 2017, 130, s. 1889–1897.
- 7 EHA 2022; abstrakt S196, Hemasphere, červen 2022.

Ultomiris (ravulizumab) v léčbě paroxysmální noční hemoglobinurie

MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika FN Brno

- 1 Lee, J. W. – Sicre de Fontbrune, F. – Wong Lee Lee, L., et al.: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*, 2019, 133, s. 530–539.
- 2 Kulasekaraj, A. G. – Hill, A. – Rottinghaus, S. T., et al.: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*, 2019, 133, s. 540–549.
- 3 Brodsky, R. A. – Peffault de Latour, R. – Rottinghaus, S. T., et al.: A prospective analysis of breakthrough hemolysis in 2 phase 3 randomized studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Blood*, 2018, 132, suppl. 1, s. 2330.
- 4 Bhak, R. H. – Mody-Patel, N. – Bayer, S. B., et al.: Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. *Curr Med Res Opin*, 2021, 37, s. 1913–1923.

Přínos profylaktické aplikace koncentráту VWF/FVIII u pacienta s typem 3 von Willebrandovy choroby

MUDr. Petr Smejkal, Ph.D. Oddělení klinické hematologie, Katedra laboratorních metod LF MU a FN Brno

- 1 Sadler, J. E. – Budde, U. – Eikenboom, J. C., et al.: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *J Thromb Haemost*, 2006, 4, s. 2103–2114.
- 2 Lillicrap, D.: The basic science, diagnosis and clinical management of von Willebrand disease. *Treatment of Hemophilia*. 2008, 35, s. 1–18, dostupné z: <https://www1.wfh.org/publications/files/pdf-1180.pdf>, vyhledáno 4. 4. 2023.
- 3 Fogarty, H. – Doherty, D. – O'Donnell, J. S.: New developments in von Willebrand disease. *Br J Haematol*, 2020, 191, s. 329–339.
- 4 Boender, J. – Eikenboom, J. – van der Bom, J. G., et al.: Clinically relevant differences between assays for von Willebrand factor activity. *J Thromb Haemost*, 2018, 16, s. 2413–2424.
- 5 Hillarp, A., et al.: The Nordic working group on von Willebrand disease responsible for the revision of this dokument. Nordic guidelines for diagnosis and management of von Willebrand disease. Guidelines of the Nordic Hemophilia Council. Final version compiled 2012-12-12, s. 1–36. Dostupné z: https://www.nordhemophilia.org/library/Files/PDF-skjol/NHC_WVD_Guidelines_rev_Final_121212.pdf, vyhledáno 4. 4. 2023.
- 6 Mannucci, P. M. – Franchini, M. – Castaman, G., et al.: Evidence-based recommendation on the treatment of von Willebrand disease in Italy. *Blood Transfus*, 2009, 7, s. 117–126.
- 7 Laffan, M. A. – Lester, W. – O'Donnell, J. S., et al.: The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guidelines approved by the British Committee for Standards in Haematology. *Br J Haematol*, 2014, 167, s. 453–465.
- 8 Connell, N. T. – Flood, V. H. – Brignardello-Petersen, R., et al.: ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. *Blood advances*, 2021, 5, s. 301–325.
- 9 Berntorp, E.: Prophylaxis in von Willebrand disease. *Haemophilia*, 2008, 14, suppl. 5, s. 47–53.
- 10 Franchini, M. – Seidzadeh, O. – Mannucci, P. – M.: Prophylactic management of patients with von Willebrand disease. *Ther Adv Hematol*, 2021, 12, s. 1–12.
- 11 Berntorp, E. – Miesbach, W.: Translating the success of prophylaxis in haemophilia to von Willebrand disease. *Thrombosis Research*, 2021, 199, s. 67–74.

ViiV Healthcare uvádí na český trh přípravky Vocabria a Rekambys, první dlouhodobě působící injekční léčivé přípravky k léčbě HIV

- 1 Souhrn údajů o přípravku pro Vocabria. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/vocabria-epar-product-information_cs.pdf, vyhledáno 21. 4. 2023.
- 2 Souhrn údajů o přípravku Rekambys. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_cs.pdf, vyhledáno 21. 4. 2023.
- 3 De Los Rios, P. – Okoli, C. – Castellanos, C., et al.: Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. *Popul Med*, 2020, 2, s. 23.
- 4 De Los Rios, P. – Okoli, C. – Castellanos, C., et al.: Physical, emotional and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study. *AIDS Behav*, 2021, 25, s. 961–972.
- 5 Swindells, S. – Andrade-Villanueva, J. F. – Richmond, G., et al.: Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. *N Engl J Med*, 2020, 382, s. 1112–1123.
- 6 Orkin, C. – Arasteh, K. – Hernandez-Mora, M. G., et al.: Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. *N Engl J Med*, 2020, 382, s. 1124–1135.
- 7 Overton, E. T. – Richmond, G. – Rizzardini, G., et al.: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomized, multi-centre, open-label, phase 3b, non-inferiority study. *Lancet*, 2021, 396, s. 1994–2005.

Léčba Castlemanovy choroby: od klasické chemoterapie po biologickou léčbu

prof. MUDr. Zdeněk Adam, CSc. | prof. MUDr. Marta Krejčí, Ph.D. | prof. MUDr. Luděk Pour, Ph.D.

Interní hematologická a onkologická klinika LF MU a FN Brno

- Fajgenbaum, D. C. – Uldrick, T. S. – Bagg, A., et al.: International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. *Blood*, 2017; 129 (12): 1646–1657.
- van Rhee, F. – Voorhees, P. – Dispenzieri, A., et al.: International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. *Blood*, 2018, 132, s. 2115–2124.
- van Rhee, F. – Oksenhendler, E. – Srkalovic, G., et al.: International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. *Blood Adv*, 2020, 4, s. 6039–6050.
- Wu, D. – Lim, M. S. – Jaffe, E. S.: Pathology of Castleman disease. *Hematol Oncol Clin North Am*, 2018, 32, s. 37–52.
- Koukalová, R. – Selingerová, I. – Řehák, Z.: FDG-PET/CT v diagnostice a hodnocení léčebné odpovědi Castlemanovy choroby – retrospektivní studie 29 případů z jednoho centra. *Klinická onkologie*, 2021, 34, s. 120–127.
- Mohan, M. – Meek, J. C. – Meek, M. E., et al.: Combinatorial treatment for unresectable unicentric Castleman disease. *Eur J Haematol*, 2021, 107, s. 484–488.
- Bandera, B. – Ainsworth, C. – Shikle, J., et al.: Treatment of unicentric Castleman disease with neoadjuvant rituximab. *Chest*, 2010, 138, s. 1239–1241.
- Abid, M. B. – Peck, R. – Abid, M. A., et al.: Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? *Hematol Oncol*, 2018, 36, s. 320–323.
- Shoji, F. – Takase, K. – Kozuma, Y., et al.: Induction immunotherapy followed by surgery for hilar unicentric Castleman disease. *Thorac Cancer*, 2022, 13, s. 1722–1725.
- Herrada, J. – Cabanillas, F. – Rice, L., et al.: The clinical behavior of localized and multicentric Castleman disease. *Ann Intern Med*, 1998, 128, s. 657–662.
- Liu, A. Y. – Nabel, C. S. – Finkelman, B. S., et al.: Idiopathic multicentric Castleman's disease: a systematic literature review. *Lancet Haematol*, 2016, 3, s. e163–e175.
- Dong, Y. – Zhang, L. – Nong, L., et al.: Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. *Ann Hematol*, 2018, 97, s. 1641–1647.
- Gérard, L. – Bérezné, A. – Galicier, L., et al.: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castleman B Trial. *J Clin Oncol*, 2007, 25, s. 3350–3356.
- Gérard, L. – Michot, J. M. – Burcheri, S., et al.: Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. *Blood*, 2012, 119, s. 2228–2233.
- Ide, M. – Ohnishi, H. – Fukumoto, T., et al.: Re-evaluation of rituximab therapy for idiopathic Castleman disease: Retrospective study from single-center experience. *Eur J Haematol*, 2022, 108, s. 354–355.
- Adam, Z. – Szturz, P. – Kfen, L.: PET-CT dokumentovaný rychlý nástup léčebné odpovědi cyklofosfamidu, thalidomidu a dexametazonu u multicentrické formy Castlemanovy nemoci. Popis případu a přehled informací o léčbě. *Vnitřní lékařství*, 2013, 59, s. 301–312.
- Ramasamy, K. – Gandhi, S. – Flowers, M. T., et al.: Rituximab and thalidomide combination therapy for Castleman disease. *Brit J Haematol*, 2012, 158, s. 421–423.
- Stary, G. – Kohrgruber, N. – Herneth, A. M., et al.: Complete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomide. *AIDS*, 2008, 22, s. 1232–1234.
- Zhang, L. – Zhao, A. L. – Duan, M. H., et al.: Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. *Blood*, 2019, 133, s. 1720–1728.
- Adam, Z. – Pour, L. – Krejčí, M.: Účinnost lenalidomidu u vzácných krevních chorob: u histiocytózy z Langerhansových buněk, multicentrické Castlemanovy choroby, POEMS syndromu, Erdheimov-Chesterovy choroby a angiomatózy. Popis případů a přehled literatury. *Vnitřní lékařství*, 2012, 58, s. 856–866.
- Zhou, X. – Wei, J. – Lou, Y., et al.: Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases. *Front Med*, 2017, 11, s. 287–292.
- Cai, S. – Zhong, Z. – Li, X., et al.: Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report. *Medicine*, 2019, 98, s. e17681.
- Hess, G. – Wagner, V. – Kreft, A., et al.: Effects of bortezomib on proinflammatory cytokine levels and transfusion dependency in patient with multicentric Castleman disease. *Brit J Haematol*, 2006, 134, s. 602–605.
- Sobas, M. A. – Alonso Vence, N. – Diaz Arias, J., et al.: Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to POEMS syndrome (MCD-POEMS variant). *Ann Hematol*, 2010, 89, s. 217–219.
- Khan, A. A. – Siraj, F. – Bhargava, M., et al.: Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib. *BMJ Case Rep*, 2012, 2012, bcr2012007646, doi: 10.1136/bcr-2012-007646.
- Zhang, L. – Zhang, M. Y. – Cao, X. X., et al.: A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. *Leuk Lymphoma*, 2022, 63, s. 618–626.
- Song, S. N. – Tomosugi, N. – Kawabata, H., et al.: Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. *Blood*, 2010, 116, s. 3627–3634.
- Kurzrock, R. – Voorhees, P. M. – Casper, C., et al.: A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. *Clin Cancer Res*, 2013, 19, s. 3659–3670.
- van Rhee, F. – Wong, R. S. – Munshi, N., et al.: Siltuximab for multicentric Castleman's disease. A randomized double blind placebo controlled trial. *Lancet Oncol*, 2014, 15, s. 966–974.
- van Rhee, F. – Casper, C. – Voorhees, P. M., et al.: Phase 2 open labeled multicenter study of long term safety of siltuximab in patients with multicentric Castleman's disease. *Oncotarget*, 2015, 6, s. 30408–30419.
- van Rhee, F. – Rossi, J. F. – Simpson, D., et al.: Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. *Br J Haematol*, 2021, 192, s. e28–e31.
- Lang, E. – Sande, B. – Brodtkin, S., et al.: Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. *Ther Adv Hematol*, 2022, 13, 20406207221082552.
- van Rhee, F. – Rosenthal, A. – Kanhai, K., et al.: Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. *Blood Adv*, 2022, 6, s. 4773–4781.
- Chrysochoou, S. – Kreft, A. – Schneider, E.: Siltuximab-related favorable clinical outcome for a patient suffering from idiopathic multicentric Castleman disease. *Case Rep Hematol*, 2022, 2022, 1840589.
- Ebisawa, K. – Shimura, A. – Honda, A., et al.: Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. *Leuk Lymphoma*, 2021, 62, s. 614–619.
- Morra, D. E. – Pierson, S. K. – Shilling, D., et al.: Predictors of response to anti-IL-6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. *Br J Haematol*, 2019, 184, s. 232–241.
- Galeotti, C. – Tran, T. A. – Franchi-Abella, S., et al.: IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report. *J Pediatr Hematol Oncol*, 2008, 30, s. 920–924.
- El-Osta, H. – Janku, F. – Kurzrock, R.: Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). *Mol Cancer Ther*, 2010, 9, s. 1485–1488.
- Jouvray, M. – Terriou, L. – Meignin, V., et al.: Pseudo-adult Still's disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: An atypical presentation of multicentric Castleman's disease. Discussion of TAFRO syndrome. *Rev Med Interne*, 2016, 37, s. 53–57.
- Ferrero, S. – Ragaini, S.: Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. *J Med Case Rep*, 2021, 15, s. 105.
- Lanzillotta, M. – Sant'Angelo, M. – Kaneko, N., et al.: Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. *Eur J Intern Med*, 2021, 87, s. 121–123.
- Borocco, C. – Ballot-Schmit, C., et al.: The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. *Orphanet J Rare Dis*, 2020, 15, s. 95.
- Soudet, S. – Fajgenbaum, D. – Delattre, C., et al.: Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. *Curr Res Transl Med*, 2018, 66, s. 83–86.
- Yamaga, Y. – Tokuyama, K. – Kato, T., et al.: Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome. *Intern Med*, 2016, 55, s. 185–190.
- Fajgenbaum, D. C.: Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. *Blood*, 2018, 132, s. 2323–2330.
- Koga, T. – Hagimori, N. – Takemori, S.: Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial. *Medicine*, 2020, 99, s. e20710.
- Stern, R. M. – Berliner, N.: Targeting the mTOR pathway in idiopathic multicentric Castleman disease. *J Clin Invest*, 2019, 129, s. 4086–4088.
- Bayram, E. – Pehlivan, U. A. – Fajgenbaum, D. C., et al.: Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. *Am J Hematol*, 2023, 98, s. 361–364.
- Shi, Y. – Li, J. – Zhang, L.: Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report. *Ann Hematol*, 2022, 101, s. 2529–2531.
- Sevindik, O. G. – Mutlu, Y. G. – Aydin, B. B., et al.: First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of Castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS). *Hemasphere*, 2022, 6, s. e728.
- Repetto, L. – Jaiprakash, M. P. – Selby, P. J., et al.: Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation. *Hematol Oncol*, 1986, 4, s. 213–217.
- Ganti, A. K. – Pipinos, I. – Culcea, E., et al.: Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. *Am J Hematol*, 2005, 79, s. 206–210.
- Tal, Y. – Haber, G. – Cohen, M. J., et al.: Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant. *Int J Hematol*, 2011, 93, s. 677–680.
- Wang, Z. – Yang, S. – Zhu, Z., et al.: Case of successful allogeneic hematopoietic stem cell transplantation for HHV8-positive Castleman's disease with a review of the literature. *Cell Transplant*, 2020, 29, 963689720943571.
- Fujimoto, S. – Kawabata, H. – Sakai, T., et al.: Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. *Int J Hematol*, 2021, 113, s. 73–80.
- Yu, L. – Shi, M. – Cai, Q., et al.: A novel predictive model for idiopathic multicentric Castleman disease: The International Castleman Disease Consortium Study. *Oncologist*, 2020, 25, s. 963–973.
- Fang, X. – Sun, Z. – Xu-Monette, Z. Y., et al.: Predictive model for idiopathic multicentric Castleman disease supporting treatment decisions. *Oncologist*, 2021, 26, s. 4–6.
- Adam, Z. – Pour, L. – Zeman, D., et al.: *Vzácné choroby provázené hypergammaglobulinémií a zánětlivými projevy*. Praha, Grada Publishing, 2022.